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Anaplastic astrocytomas are aggressive glial cancers that present poor prognosis and
high recurrence. Heterozygous IDH1 R132H mutations are common in adolescent and
young adult anaplastic astrocytomas. In a majority of cases, the IDH1 R132H mutation is
unique to the tumor, although rare cases of anaplastic astrocytoma have been described
in patients with mosaic IDH1 mutations (Ollier disease or Maffucci syndrome). Here,
we present two siblings with IDH1 R132H mutant high grade astrocytomas diagnosed
at 14 and 26 years of age. Analysis of IDHR132H mutations in the siblings’ tumors
and non-neoplastic tissues, including healthy regions of the brain, cheek cells, and
primary teeth indicate mosaicism of IDHR132H. Whole exome sequencing of the tumor
tissue did not reveal any other common mutations between the two siblings. This
study demonstrates the first example of IDH1 R132H mosaicism, acquired during early
development, that provides an alternative mechanism of cancer predisposition.
Keywords: anaplastic astrocytoma, mosaicism, cancer predisposition, ddPCR, AYA (adolescents and young
adults), IDH1 R132H mutation
BACKGROUND
Gliomas comprise nearly one-third of newly diagnosed brain tumors in adolescents and young
adults (AYA; 15–39 years) (1). While most AYA gliomas are low grade (grade I/II), patients
who present with anaplastic astrocytomas and glioblastomas (grade III/IV) have high risk of
recurrence and poor prognosis (2). Heterozygousmutations in IDH1 genes are common alterations
in AYA gliomas, particularly in grade II diffuse astrocytomas, anaplastic astrocytomas, secondary
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glioblastomas, and oligodendrogliomas (3, 4). The most frequent
of these mutations is the IDH1 c.395 G>A (IDH1 R132H)
mutation. Genetic studies suggest that IDH1 mutations are
an early clonal event in anaplastic astrocytoma development
(5, 6). Mutations in IDH1 gene result in the production of
2-hydroxyglutarate (2HG) from alpha-ketoglutarate. The high
levels of 2HG in cells promote histone methylation and block
differentiation of progenitor cells, creating an environment that
encourages the accumulation of additional mutations, such as
TP53 and ATRX, and thus resulting in unchecked cellular
proliferation (7).
Familial gliomas are rare, and have primarily been described
in patients with inherited or sporadic germline cancer
predisposition syndromes such as Neurofibromatosis Type 1
(NF1), Li-Fraumeni syndrome (TP53), hereditary breast/ovarian
cancer syndrome (BRCA2), constitutional mismatch repair
deficiency syndrome (MLH1, MSH2, MSH6, and PMS2),
Turcot syndrome (APC), Tuberous sclerosis (TSC1/TSC2),
Melanoma-neural system tumor syndrome (p16/CDKN2A),
and POT1-associated familial gliomas (8–10). Inherited risk
variants, such as those near the genes TERC, TERT, EGFR,
CDKN2B, PHLDB1, RTEL, TP53, and CCDC26, may also
contribute to glioma formation (10–15). Of these, patients with
inherited risk variants near CCDC26 (allele G in rs55705857)
have the highest risk of developing IDH1/2-mutant gliomas,
although tumor penetrance in patients who carry these variants
is low (14). Somatic mosaic mutations can also predispose to
glioma development. Patients with Ollier disease and Maffucci
syndrome, which are rare enchondromatosis syndromes, have
been shown to carry mosaic mutations of IDH1, including
IDHR132H (16, 17). The most common tumors in patients
with IDH1 mosaic mutations are multiple enchondroma and
cavernous hemangiomas (Maffucci), but anaplastic astrocytomas
have also been reported (17, 18). Recent studies have shown
that somatic mosaicism resulting from mutations acquired
during embryonic development can influence the likelihood of
developing cancer in adulthood (19).
MATERIALS AND METHODS
Ethics Approval and Consent for
Publication
This study was approved and carried out in accordance with
Children’s National Hospital’s Institutional Review Board (IRB
#1339 and #6778). All adult subjects, and in the case of sibling A
(minor) his parents, gave written informed consent in accordance
with the Declaration of Helsinki to the publication of results and
the collection and analysis of specimens utilized in this study
including post-mortem whole brain of sibling A, resected tumor
specimens, whole blood and cheek swab of sibling B, whole blood
and cheek swabs of family members, healthy-donor teeth.
Abbreviations: AYA, adolescents and young adults; 2HG, 2-hydroxyglutarate;
DNA, deoxyribonucleic acid; ddPCR, digital droplet polymerase chain reaction;
WES, whole exome sequencing; MRI, magnetic resonance imaging; DCX,
doublecortin; IHC, immunohistochemistry; MAF, mutation allelic frequency;
DIPG, diffuse intrinsic pontine glioma.
Please see Supplementary Materials for additional materials
and methods used in this publication.
CASE PRESENTATION
Clinical Presentation of Siblings With IDH1
R132H Mutant Astrocytoma
Two AYA siblings presented with anaplastic astrocytoma. Sibling
A (Male) presented at 14 years of age with a large non-enhancing
left temporal mass (Figures 1A,A′) and a pathological diagnosis
of Grade III/IV astrocytoma. Treatment for his tumor included
radiation therapy, chemotherapy (Temozolamide+metronomic
chemotherapy), and vaccine therapy through a clinical trial.
Despite therapy, his tumor continued to progress, and he passed
away 5 years after diagnosis. His family opted to donate his
whole brain and tumor to the Children’s Research Institute
at Children’s National Health System at post mortem. Sibling
B (Female) presented to medical attention after experiencing
a seizure, 1 year after sibling A passed away. She was also
noted to have a right temporal lobe non-enhancing mass
(Figures 1B,B′). She was initially treated with surgery alone, and
pathology showed a Grade II/III astrocytoma. At recurrence,
1 year after diagnosis, pathology revealed a more aggressive
Grade III/IV astrocytoma. She had surgery followed by radiation
and chemotherapy (Temozolamide +metronomic therapy). She
developed additional tumors in the pons and spinal cord, and
she passed away just over 2 years following her diagnosis.
Biospecimens were not available for post-mortem analysis.
Both sibling A and sibling B’s tumors were noted to have
IDHR132H mutant protein expression on IHC. To assess the
allelic frequency of the mutation, DNA was obtained from
frozen tumor (both cases) and analyzed by ddPCR. Analysis
showed mutation allelic frequencies of 47.8% (for sibling A)
and 63.1% (sibling B) indicating the heterozygous status of
IDH1 c.395 G>A (IDHR132H) mutation (Figures 1C,D). Given
similarities in tumor pathology and their presentation, a cancer
predisposition syndrome was strongly suspected. Sibling B
was evaluated in cancer genetics clinic at Children’s National
where three generation pedigree was obtained and did not
suggest a specific familial cancer predisposition syndrome on
the maternal or paternal side of the family (Figure 1E). Clinical
whole exome trio sequencing of blood DNA from sibling B
and her parents was performed. A maternally inherited PTCH2
variant of unclear significance was identified, but no pathogenic
mutations pertaining to inherited glioma predisposition
were detected.
Temporal Detection of IDH1 R132H in
Sibling a at Post Mortem
To further investigate potential genetic similarities between the
two siblings, DNA was extracted from both tumors to be assessed
by whole exome sequencing (WES). Sibling A did not have whole
blood, cheek swab, or skin DNA to use as a normal control; hence
the only available source of germline DNA was the unaffected
postmortem brain tissue. Recognizing the diffuse nature of these
tumors, both IHC and ddPCR for the IDHR132H mutation were
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FIGURE 1 | Clinical presentation of siblings with IDH1 R132H mutant astrocytoma. (A,A′) T2 and T1 contrast MRI showing a left temporal mass in Sibling A. (B,B′) T2
and T1 contrast MRI showing a right temporal mass in Sibling B. (C) Digital droplet PCR (ddPCR) analysis of Sibling A’s tumor showing mutation allelic frequencies of
47.8%. (D) Digital droplet PCR (ddPCR) analysis of Sibling B’s tumor showing allelic frequencies of 63.1%. (E) Pedigree of the family.
performed on non-neoplastic brain regions (as indicated by
MRI), including right pons, frontal, parietal, and occipital lobes.
IHC and ddPCR indicated the presence of IDHR132H mutation
in all the tested regions (Figures 2A,B). IDH1R132H was seen
in only a fraction of the cells in these regions indicating the
variation is mosaic and not in every cell. Interestingly, in the
tumor most of the IDH1R132H positive cells had morphology
consistent with glia cells (Figure 2A), but in the other regions of
the brain, such as the pons and the frontal lobe, the IDH1R132H
positive cells primarily showed features that resembled neurons
(Figure 2A top and middle panels). Although not all IDH
mutant astrocytic tumors co-occur with mutations or alterations
in p53, since the patient’s tumor cells showed p53 protein
expression by IHC (Figure 2A bottom panel), IHC for p53 was
performed on all the other regions of the brain, to determine
if the IDHR132H mutant cells are infiltrating tumor cells. All
the regions tested were negative for p53 except the frontal lobe,
where rare p53-positive glia cells were identified (Figure 2A
lower panel, arrowhead). Immunofluorescent staining
revealed co-localization of IDHR132H mutation and DCX,
an immature neuron marker, in the pons (Figures 2CA′–D′)
confirming that IDHR132H positive cells are indeed young
neurons and not infiltrating tumor cells. This pattern of
IDHR132H and DCX co-localization was not seen in sibling
A’s tumor (Figures 2CE′–H′).
IDH1 Mosaicism Revealed by Presence of
IDH1 R132H in Other Biospecimens
Suspecting that sibling A has a unique mosaic pattern of
IDHR132H mutant cells, alternative specimens that would provide
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FIGURE 2 | Temporal detection of IDH1 R132H in Sibling A at post mortem. (A) Immunohistochemical analysis of post-mortem brain of Sibling A indicating presences
of IDHR132H mutant cells in the tumor and other non-neoplastic regions of the brain. p53 immunohistochemistry confirms that there are no infiltrating tumor cells in
other regions of the brain (scale bar = 50µm). (B) Mutation allelic frequency of IDHR132H detected in frontal lobe, temporal lobe, parietal lobe, occipital lobe, and pons
by ddPCR. (C) Immunofluorescent staining of the pons indicating co-localization of IDHR132H and DCX (arrowheads in D′ ). Similar pattern of co-localization of
IDHR132H and DCX is absent in the tumor (arrows in H′ ) (scale bar = 30µm).
germline DNA were requested from the family. Sibling A’s
toothbrush (last used 4 years prior to analysis) and primary
deciduous teeth were obtained. The toothbrush was processed
in a Tris base solution prior to DNA extraction (see Methods
and Figure S1A). DNA from deciduous teeth was extracted
by pulverization with liquid nitrogen (see Methods and
Figure S1B). DNA from deciduous teeth was quantified and
showed a linear relationship between the tooth weight and the
amount of DNA isolated (Figures S1C,C′). In order to assess
the feasibility of detecting single nucleotide variation in DNA
isolated from the teeth and toothbrush, ddPCR using probes for
wild-type histone H3F3A was performed. The H3F3A histone
DNA was detected in both the teeth and toothbrush DNA
(Figures S1D,E). As expected, there were significantly fewer
DNA copies in the toothbrush (Figure S1E) than in the teeth
samples (Figure S1D). DNA isolated from the teeth and the
toothbrush of sibling A was then analyzed for the IDH1R132H
mutation via ddPCR. The toothbrush DNA did not contain
any IDH1R132H mutant copies, which was likely affected by the
very low levels of DNA (Figures 3A,C). The teeth DNA showed
IDH1R132H copies at average mutant allelic frequency (MAF)
of 0.18% (Figures 3A,B). To eliminate possible contamination
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FIGURE 3 | Presence of IDH1 R132H in other biospecimens. (A) Mutation allelic frequency of IDHR132H detected in Sibling A’s teeth and toothbrush by ddPCR. (B)
ddPCR plot of Sibling A’s tooth, showing the copy number of wild-type IDH1 and copy number of IDHR132H. (C) ddPCR plot of Sibling B’s toothbrush, showing the
copy number of wild-type IDH1 and the absence of IDHR132H. (D) Mutation allelic frequency of IDHR132H detected in Sibling B’s cheek swab and whole blood by
ddPCR. (E) ddPCR plot of Sibling B’s cheek swab, showing the copy number of wild-type IDH1 and copy number of IDHR132H. (F) ddPCR plot of Sibling B’s whole
blood, showing the copy number of wild-type IDH1 and copy number of IDHR132H.
or experimental errors, ddPCR on DNA extracted from teeth
donated by 7 healthy individuals was analyzed to validate the
findings (Figure S2A). As expected, IDH1R132H mutant copies
were not detected, validating the sensitive detection of an
IDH1R132H mutation by ddPCR in the deciduous teeth DNA
of sibling A. This finding, along with the IDH1R132H mutation
pattern in the brain, supports the presence of IDH1R132H somatic
mosaicism in sibling A.
Detection of IDH1 R132H in Tumor and
Indications of Somatic Mosaicism in
Sibling B
Sibling B was diagnosed with an astrocytoma of the right
temporal lobe (Figure 1B). During the course of her treatment,
sibling B had two biopsies of a suspicious region (T2 bright on
MRI) in the left frontal cortex that showed reactive gliosis (biopsy
1) and hyperplasia (biopsy 2) (Figures 4A,B), but no obvious
tumor. Both biopsy specimens were noted to be IDHR132H
negative by IHC (Figures 4A′,B′). DNA was extracted from the
biopsy specimens to perform ddPCR for IDHR132H. IDHR132H
was detected with an MAF of (0.60%) and (1.08%) for biopsy 1
and 2, respectively (Figures 4A′′,B′′). This supports that sibling
B also had a low level of IDHR132H mosaicism in non-neoplastic
brain regions.
To test whether sibling B exhibited a similar pattern of somatic
mosaicism as sibling A, DNA isolated from cheek swabs and
whole blood DNA was examined. Interestingly, the cheek swab
and whole blood of sibling B revealed IDHR132H mutant copies
at an average MAF of 0.07 and 0.13%, respectively, indicating
a similar mosaic pattern to that observed in the other germline
biospecimens of sibling A (Figures 3D–F). To further confirm
this finding, DNA from deciduous teeth of sibling A, and DNA
from a cheek swab of sibling B were analyzed by next generation
sequencing (NGS). This data confirmed the ddPCR findings,
where IDHR132H mutant copies were present at very low levels
(MAF of 0.29%, and 0.01% for teeth of sibling A and cheek swab
of sibling B, respectively) (Figures S2B,C).
Since IDHR132H mosaicism in two siblings is rare, other
potential explanations for the findings were considered. Our
laboratory has previously shown that H3.3K27M somatic
mutations can be found in circulating tumor DNA (plasma)
of children diagnosed with DIPG (20). Similarly, IDHR132H
mutations can be detected in CSF, and less consistently in plasma
of patients with IDHR132H positive tumors using ddPCR (21, 22).
In order to rule out the presence of circulating tumor DNA
in the cheek swab specimen obtained from sibling B, cheek
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FIGURE 4 | Detection of IDH1 R132H in the frontal lobe biopsy of sibling B and parental whole blood. (A) Hematoxylin & eosin staining of the biopsied frontal lobe
tissue shows reactive gliosis (scale bar = 50µm). (A′) Immunohistochemical analysis of the biopsied frontal lobe tissue shows absence of IDHR132H mutant cells. (A′′)
ddPCR analysis of the DNA isolated from the biopsied frontal lobe tissue shows IDHR132H mutational allelic frequency of 0.60%. (B) Hematoxylin & eosin staining of
the biopsied frontal lobe tissue shows hyperplasia. (B′) Immunohistochemical analysis of the biopsied frontal lobe tissue shows absence of IDHR132H mutant cells.
(B′′) ddPCR analysis of the DNA isolated from the biopsied frontal lobe tissue shows IDHR132H mutational allelic frequency of 1.08%. (C) ddPCR analysis of maternal
whole blood shows mutant allelic frequency average of 0.007%. (D) ddPCR analysis of paternal whole blood shows absence of IDHR132H mutant copies.
swabs from two patients diagnosed with diffuse intrinsic pontine
glioma (DIPG) with known H3.3K27M mutations (as confirmed
by tumor biopsy) were collected. ddPCR was performed on
the DNA extracted from the cheek swabs and matched plasma
specimens. Despite positive results in the plasma, the H3.3K27M
mutation was not found in the cheek swabs from these patients
(Figure S3A). Since patients with IDHR132H mutant tumors
may behave differently than patients with DIPG, ddPCR was
also performed on cheek swab DNA from two additional
patients diagnosed with IDHR132H positive tumors (one with
a progressive tumor, and the other with multifocal tumors).
Cheek swab samples from these two patients were negative
for IDHR132H by ddPCR analysis (Figure S3B). In summary,
the findings suggest that this is a case of IDHR132H somatic
mosaicism in two siblings, predisposing them to the development
of IDH1-mutant glial tumors.
Detection of IDH1 R132H in Maternal Blood
Given the possibility of genetic or environmental exposures to
developing the IDHR132H mutation, ddPCR was performed on
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parental (mother and father) blood samples. The variant was
not detected in paternal blood but was identified at low levels
(0.007%) in the maternal blood sample (Figures 4C,D). Cheek
swabs from both parents did not contain the IDHR132H variant
(data not shown).
DISCUSSION
Familial gliomas without obvious genetic predisposition are
rare, and when they are reported, the underlying etiology often
remains a mystery (23). In this case, two siblings, one male, and
one female, both had IDHR132H mutant anaplastic astrocytomas
without obvious genetic predisposition. Although common
inherited risk variants could not be assessed, since whole genome
sequencing results on either sibling was not available, shared
exonic germline mutations associated with familial gliomas were
not identified through clinical trio sequencing of patient B
and her parents. Whole exome sequencing of tumor/normal
DNA (using frontal lobe DNA from sibling A and blood DNA
from sibling B) was performed, and, aside from the IDHR132H
mutation, WES did not reveal any other shared mutations in the
tumor (Figures S4A–C).
Somatic mosaicism occurs when a select number of cells
within a developing embryo acquire a mutation that is not
corrected through DNA repair mechanisms and is therefore
allowed to persist, creating two distinct populations of cells (24).
The phenotypic effect of mosaic mutations is dependent on when
the mutation occurs during development, with early mutations
affecting a larger number of cells than late mutations. In siblings
A and B, the IDHR132H mutation was noted in cells obtained
from more than one tissue including blood, cheek cells, healthy
brain tissue, and teeth. This evidence, along with the early onset
of tumor formation in both patients, strongly suggests that the
IDHR132H mutation occurred during embryonic development.
Yet, only the brain glia cells, which acquired additional somatic
mutations (such as TP53 andATRX) formed a tumor (Figure 2A,
Figures S4B,C).
Somatic mosaicism of the same gene in two siblings is
extremely rare, and we were not able to find any reports of
this occurring in the literature. Although the exact underlying
etiology for the somatic mosaicism in these patients is still
unknown, it is possible that environmental exposures may have
played a role. It is also possible that there is an underlying
genetic predisposition that has not yet been discovered. The
somatic mosaicism of this variant in the mother, with low levels
identified in her blood but not in her cheek swabs, supports either
a maternal environmental exposure or a maternally inherited
genetic risk factors predisposing to selection of the IDHR132H
mutation. An alternative hypothesis includes persistent fetal
microchimerism, where the levels detected in the mother
represent persistence of cells from her previous pregnancies.
This case highlights an important concept in cancer
predisposition and cancer development by providing direct
evidence that low level IDHR132H mosaicism, even in patients
without classic Ollier or Maffucci syndrome, can predispose
to glioma formation. A similar phenomenon has already been
described in patients with somatic mosaic mutations in TSC1/2,
TP53, APC, RB1, and BRCA1 who have increased risk of
developing cancer in multiple tissue types (19, 25–29). Although
the incidence of somatic mosaicism in most of these cancer
predisposition genes is not known, a recent report of patients
with clinical Tuberous Sclerosis Complex but negative germline
TSC1/2 testing revealed mosaicism in 26 of 53 (49%) patients
tested, with 5 patients having an allele fraction of <1% by NGS
(29). Since 10–15% of patients with TSC are germline negative,
this suggests that up to 7.5% of children with TSC have somatic
mosaicism. Without highly sensitive methods such as ddPCR
used to detect the low-level mosaicism, the mosaic IDHR132H
mutant cells likely would have been missed in sibling A and B.
Thus, it is very likely that somatic mosaicism of IDHR132H and
other mutations is more common than previously recognized.
Although ddPCR from two other patients with IDHR132H mutant
tumors did not reveal the mutation (Figure S3B), a larger
analysis of multiple patients with IDHR132H mutant tumors
would be required to determine if this was truly unique to this
sibling pair, or if other patients harbor similar mosaicism.
Increased awareness of early somatic mosaic mutations
contributing to cancer development in children and young adults
will improve our understanding of tumorigenesis. Therefore,
further research is required to tease apart the mechanisms
of IDHR132H somatic mosaicism and its contribution to
glioma predisposition. Ultimately, recognizing this alternative
mechanism of cancer predisposition is critical for early detection
and management of patients at risk.
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